Transcriptome-based identification of PDGFA as a candidate secreted biomarker for hepatocellular carcinoma

Abstract

Aim. Identification of candidate secreted biomarkers for hepatocellular carcinoma (HCC) diagnosis. Methods. Genes upregulated in HCC tissue and encoding secreted proteins were identified by RNA-seq. Gene expression changes in HCC were evaluated by RT-qPCR and meta-analysis of public databases. Biomarker properties were studied using ROC-curves, correlation and survival analysis. Results. PDGFA was identified by RNA-seq as an overexpressed gene encoding for a secreted protein in 5 HCC cases. PDGFA and GPC3 upregulation was revealed in 17 of 19 HCC samples and in most cases from the public databases. Combination of PDGFA and GPC3 discerned HCC and non-tumor tissue better than PDGFA or GPC3 alone. PDGFA overexpression was associated with better overall survival of the patients at early HCC stage and with weaker tumor invasion into blood vessels. Conclusion. PDGFA is a valuable secreted biomarker for HCC that might be used in combination with GPC3 to increase its sensitivity. K e y w o r d s: hepatocellular carcinoma, PDGFA, tumor biomarker, NGS ISSN 1993-6842 (on-line); ISSN 0233-7657 (print)

Impact of HNF4α disrupted expression on hepatocellular carcinoma cells sensitivity to oncogenic pathways inhibitors

“…Количество комплементарной ДНК в образцах нормировали по уровню экспрессии гена ТВР. Постановку ПЦР-РВ и обработку данных выполняли, как описано ранее [15].…”